Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to activate a photoactive pharmaceutical (photosensitizer) to create a photodynamic reaction. Current photodynamic therapy devices out on the market are around 20 years old and the companies that manufacture the devices, do not provide yearly maintenance services for the devices. Therefore, Modulight has developed the multi-indication ML6710i ophthalmic laser platform and the beam shaping unit ML-SLA to address the need for supported PDT equipment and to target the treatment of oncological and various other diseases affecting the posterior of the eye with the capability to provide laser light ranging from 400 nm to 2000 nm depending on the specific customer needs. ML-SLA has been tested to yield a superior beam quality and enable a larger spot size range than any existing beam shaping unit in the market, thus eliminating the need for multi-spot treatment of larger lesions. The device connects to Modulight Cloud services, enhancing treatment planning and post-operative analysis. In addition, the ML6710i laser platform has the capability of including a camera module to record the intra-operative fundus view into Modulight Cloud to further assist in post-operative treatment analysis.
Delivery of pharmaceuticals to the eye posterior poses a major challenge in ophthalmology. A promising drug delivery platform is indocyanine green (ICG) liposomes, which absorb near-infrared light resulting in a release of pharmaceutical molecules. The Modulight ophthalmic laser platform has been designed for treatments targeting the eye posterior and can also excite the absorption band of the liposomes. The laser connects with Modulight Cloud, enabling artificial intelligence (AI) based treatment planning by correlating the treatment parameters and success, which could increase the efficacy of future treatments. The same algorithms could deduce which treatment parameters work with which liposomal delivery parameters.
Photodynamic therapy is a cancer treatment modality with great potential but moderate clinical success. One reason for the sub-optimal clinical success is the limited knowledge about light distribution in tissues and lack of ways to monitor treatment real-time. Modulight has developed a laser platform for glioblastoma which will utilize real-time treatment monitoring based on spectral properties of the tissue and the drug. This therapy modality is based on photodynamic therapy with 5-aminolevulinic acid (5-ALA) primarily because the approved use of 5-ALA in fluorescence guided resections for glioblastoma and because of the known photobleaching properties of 5-ALA metabolite Protoporphyrin-IX (PPIX). Photobleaching means the photochemical alteration of a dye or a fluorophore in a way that it becomes permanently unable to fluoresce, and the real-time spectral monitoring is based on monitoring the intensity of PPIX fluorescence emission at 703 nm upon excitation with treatment wavelength 635 nm. Modulight glioblastoma platform enables monitoring PPIX fluorescence throughout the treatment to inspect the decline in fluorescence intensity. This photobleaching phenomenon represents the time region where the maximal therapeutic effect occurs so the ability to monitor this would ultimately enable optimizing the treatment time individually for each patient. Novel Modulight lasers are internet connected so that the treatment monitoring data can be immediately uploaded to cloud improving data management and review and possible future machine learning and AI based medicine.
Different wavelength lasers are widely used in ophthalmology for example for selectively heating certain tissues of the eye or unleashing the potential of photoactive pharmaceuticals. The problem with many ophthalmic laser-based treatments such as photodynamic therapy for age-related macular degeneration is that the laser technology is outdated and no longer supported despite the wide clinical use of these therapy modalities. Modulight has developed a configurable cloud-connected ophthalmic laser device that can house any of Modulight’s semiconductor lasers and is wirelessly controlled with an iPad. In addition to novel ophthalmic laser technology, Modulight has also developed a novel beam shaping unit which yields superior beam quality and enables exceptionally large treatment spots eliminating the need for multi-spot treatment for larger lesions.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.